Research Keywords: 1-vessel Obstructive Coronary Artery Disease (1-vessel Obstructive Cad); 5-ht2 Receptor Antagonists; Ablation; Ace Inhibitors; Acute Coronary Syndrome (acs); Acute Coronary Syndromes; Acute Myocardial Infarction; Advance Directives; Aldosterone Antagonists; Alirocumab... [+]

Research Keywords: 1-vessel Obstructive Coronary Artery Disease (1-vessel Obstructive Cad); 5-ht2 Receptor Antagonists; Ablation; Ace Inhibitors; Acute Coronary Syndrome (acs); Acute Coronary Syndromes; Acute Myocardial Infarction; Advance Directives; Aldosterone Antagonists; Alirocumab; All-cause Mortality; Ambrisentan; Amlodipine Sildenafil; Anacetrapib; Andexanet Alfa; Angiotensin Receptor Blockers; Angiotensin-converting Enzyme Inhibitor; Angiotensin-converting Enzyme Inhibitors; Anticoagulation; Antihypertensive Agents; Antihypertensive Drug; Antihypertensive Drug Therapy; Antihypertensive Drug Therapy Cardiovascular Events; Antihypertensive Drugs; Antihypertensive Therapy; Antihypertensive Treatment; Antiplatelet Drugs; Antipsychotics; Aortic Aneurysm, Abdominal; Apo A1; Apo B100; Arrhythmias; Arterial Hypertension; Artificial Heart; Aspirin; Atenolol; Atherosclerosis; Atherosclerotic Cardiovascular Disease; Atherosclerotic Vascular Disease; Atrial Fibrillation; Atypical Antipsychotics; Balloon Pulmonary Angioplasty; Beraprost; Beta Blockers; Beta-blocker; Beta-blockers; Blood Pressure; Blood Pressure Targets; Bococizumab; Bone Mineral Density; Bosentan; Calcium Channel Blockers; Calcium-channel Blockers; Cancer; Cangrelor; Cardiac Resynchronization Therapy; Cardiac Sarcoidosis; Cardiac Support Device; Cardiac Surgery; Cardiomyopathy; Cardiovascular Disease; Cardiovascular Drugs; Cardiovascular Effects; Cardiovascular Events; Cardiovascular Morbidity; Cardiovascular Mortality; Cardiovascular Outcomes (cv Outcomes); Cardioverter-defibrillator Shocks; Carvedilol; Catheter Ablation; Cerebrovascular Events; Cetp; Chads(2) Score; Chest Pain; Cholesterol; Cholesterylester Transfer Protein; Chronic Kidney Disease; Chronic Thromboembolic Pulmonary Hypertension; Cilostazol; Clinical Competency Committee; Clopidogrel; Combination Antihypertensive Therapy; Complex Fractionated Atrial Electrograms (cfae); Computer Tomography; Congestive Heart Failure; Contrast; Contrast-enhanced Ultrasonography; Coronary Angiography; Coronary Artery Disease; Coronary Artery Disease (cad); Coronary Heart Disease; Coronary Revascularization; Coronary Risk Factors; Cteph; Culprit Lesion; Cyclic Amp; Dalcetrapib; Diabetes; Diabetes Mellitus; Diastolic Blood Pressure; Dichloroacetate; Diltiazem; Diuretics; Downhill Esophageal Varices; Drug-induced Hyperkalemia; Dyslipidemia; Dyspnea; Early Gastric Cancer; Early Invasive Strategy; Echocardiography; Educational Milestones; Elderly; Elderly Patients; Electrocardiogram ( Ecg); Embolectomy; Empagliflozin; Endothelial Nitric Oxide Synthase Couplers; Endothelin Receptor Antagonists; Entresto; Epoprostenol; Evacetrapib; Evolocumab; Exercise; Exercise Capacity; First Generation; Frail; Gastric Carcinoma; Gastrointestinal Bleeding; Glimepiride; Glucagon Like Peptide-1 Agonists; Guanylate Cyclase; Hdl-c; Health Care Proxy; Health Outcome; Health Resource Variability; Heart Failure; Heart Failure (hf); Heart Failure Readmission; Heart Failure With Reduced Ejection Fraction; Hemochromatosis; High Density Lipoprotein; High-density Lipoprotein Cholesterol; High-risk Coronary Anatomy; Hybrid Ablation; Hypercholesterolemia; Hyperlipidemia; Hypertension; Hypertrophic Cardiomyopathy; Idarucizumab; Iloprost; Imatinib; Implantable Defibrillator; In-hospital Mortality; Incidence; Infection; Inflammatory Bowel Disease (ibd); Intermittent Claudication; Iron Overload; Ischemic Cardiomyopathy; Ischemic Heart Disease; Labetalol; Lauren Classification; Lcz696; Ldl-c; Length Of Stay; Lifestyle Measures; Linagliptin; Linear Lesion; Lipid-lowering Drug; Lipid-lowering Drugs; Lipids; Liraglutide; Lomintapide; Long Standing Persistent Atrial Fibrillation (lspaf); Low Density Lipoprotein; Low-density Lipoprotein Cholesterol; Low-dose Computed Tomography Scan; Lung Cancer Screening; Lung Transplantation; Lymph Node Metastasis; Macitentan; Major Adverse Cardiac Events; Mechanism; Metformin; Metoprolol; Microbubbles; Microsomal Triglyceride Transfer Protein; Mipomerson; Monoclonal Antibodies; Mortality; Mtp; Multivessel Cad; Myocardial Infarction; Myocardial Ischemia; Myocardium; Natriuretic Peptide System; Nebivolol; Nifedipine; Nitrates; Nitric Oxide; Non-alcoholic Fatty Liver Disease; Non-st-elevation Myocardial Infarction; Non-st-elevation Myocardial Infarction (nstemi); Non-vitamin K Dependent Anticoagulants; Noncaseating Granulomas; Nonischemic Cardiomyopathy; Nonprostanoid Prostacyclin Receptor Agonists; Octogenarians; Orthotopic Heart Transplant (oht); Osteopenia; Osteoporosis; Pah; Partial Anomalous Pulmonary Venous Connection; Pcsk9; Pde-5i; Per977; Percutaneous Coronary Intervention (pci); Peripheral Arterial Disease; Ph; Phosphodiesterase Inhibitors; Phosphodiesterase-5 Inhibitors; Pioglitazone; Platelet Glycoprotein Iib/iiia Inhibitors; Potassium Supplements; Prasugrel; Prehypertension; Primary Percutaneous Coronary Intervention; Prolonged Hyperkalemia; Proprotein Converase Subtilisin/kexin Type 9; Prostacyclin; Prostanoids; Pulmonary Arterial Elastance; Pulmonary Arterial Hypertension; Pulmonary Embolism; Pulmonary Endarterectomy; Pulmonary Hypertension; Pulmonary Hypertension (ph); Pulmonary Hypertension-left Heart Disease (ph-lhd); Pulmonary Vascular Resistance; Pulmonary Vein Isolations (pvi); Qt Interval Prolongation; Qtc Interval; Quality Improvement; Quality Of Evidence; Ranolazine; Revascularization; Rho-kinase Inhibitors; Riociguat; Risk; Risk Factors; Rotors; Sacubitril/valsartan; Sarcoidosis; Second Generation; Selexipag; Semaglutide; Severe Asthma; Sitagliptin; Smoker's Paradox; Smoking; Sodium Glucose Co-transporter-2 Inhibitors; Soluble Guanylate Cyclase Stimulators; St-elevation Myocardial Infarction (stemi); St-segment Elevation Myocardial Infarction; Statin; Statins; Stroke; Sudden Cardiac Death; Superior Vena Cava Obstruction (svc Obstruction); Sympathetic Denervation; Syncope; Syncope Scores; Systolic Blood Pressure; Tadalafil; Tako-tsubo Cardiomyopathy; Tandem Heart (tm); Target Blood Pressure; Thoracic Aortic Atheroma; Thrombolysis; Ticagrelor; Torcetrapib; Torsades De Pointes; Tracheobronchitis; Transesophageal Echocardiography; Treatment; Triglycerides; Trimetazidine; Type 2 Diabetes; Type 2 Diabetes Mellitus; Type 2 Diabetes Mellitus (t2dm); Typical Antipsychotics; Tyrosine Protein Kinase Inhibitors; Ulcerative Colitis (uc); Ultrasonography; Unstable Angina; Uterine Leiomyosarcoma; Vardenafil Riociguat; Vasoactive Intestinal Peptides; Ventricular Arrhythmias; Ventricular Fibrillation; Ventricular Tachycardia; Very Low Density Lipoprotein; Vldl; Vorapaxar; Wall Motion Score Index [-]

Biography: Wilbert S Aronow MD is Professor of Medicine at New York Medical College/Westchester Medical Center, Valhalla, NY, United States. Dr. Aronow received his MD from Harvard Medical School. He has ... [+]

Biography: Wilbert S Aronow MD is Professor of Medicine at New York Medical College/Westchester Medical Center, Valhalla, NY, United States. Dr. Aronow received his MD from Harvard Medical School. He has edited 13 books and is author or co-author of 1467 papers, 317 commentaries or Letters to the Editor, and 1015 abstracts and is presenter or co-presenter of 1376 talks at meetings. Dr. Aronow is a Fellow of the ACC, the AHA, the ACP, the ACCP, the AGS (Founding Fellow of Western Section), and the GSA. He has been a member of 117 editorial boards of medical journals, editor-in-chief of 1 journal, co-editor of 2 journals, deputy editor of 1 journal, executive editor of 3 journals, associate editor for 9 journals, and guest editor for 7 other medical journals. He has received each year from 2001-2015 an outstanding teacher and researcher award from the medical residents and from 2001-2015 from the cardiology fellows at Westchester Medical Center/New York Medical College. He has received awards from the Society of Geriatric Cardiology, the Gerontological Society of America, New York Medical College including the 2014 Chancellor's Research Award, the F1000 Faculty Member of the Year Award for the Faculty of Cardiovascular Disorders in 2011, 2013, and 2014, the Walter Bleifeld Memorial Award for distinguished contributions to clinical research from the International Academy of Cardiology in July, 2010, and a Distinguished Fellowship Award from the International Academy of Cardiology in July, 2012. He has been a member of 4 national guidelines committees including being a coauthor of the 2010 AMDA guidelines for heart failure , co-chair and first author of the 2011 ACC/AHA expert consensus document on hypertension in the elderly, a coauthor of the 2015 AHA/ACC/ASH scientific statement on treatment of hypertension in patients with coronary artery disease, and is currently a member of the 2016 ACC/AHA/ AAPA ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the management of patients with hypertension. He was a coauthor of a 2015 position paper from the International Lipid Expert Forum. He was a consultant to the American College of Physicians Information and Educational Resource (PIER) on the module of aortic stenosis. He is currently a member of the Board of Directors of the ASPC and a member of the ACCP Cardiovascular Medicine and Surgery Network Steering Committee. [-]